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Abstract: Uterine leiomyomas are benign smooth muscle cell tumors originating from the
myometrium. In this study we focus on leiomyoma and normal myometrium phosphoproteome, to
identify differentially phosphorylated proteins involved in tumorigenic signaling pathways, and in
anti-apoptotic processes and cell survival. We obtained paired tissue samples of seven leiomyomas
and adjacent myometria and analyzed the phosphoproteome by two-dimensional gel electrophoresis
(2-DE) combined with immobilized metal affinity chromatography (IMAC) and Pro-Q Diamond
phosphoprotein gel stain. We used mass spectrometry for protein identification and Western blotting
for 2-DE data validation. Quantities of 33 proteins enriched by the IMAC approach were significantly
different in the leiomyoma if compared to the myometrium. Bioinformatic analysis revealed ten
tumorigenic signaling pathways and four phosphoproteins involved in both the inhibition of apoptosis
and cell survival. Our study highlights the involvement of the phosphoproteome in leiomyoma
growth. Further studies are needed to understand the role of phosphorylation in leiomyoma. Our data
shed light on mechanisms that still need to be ascertained, but could open the path to a new class of
drugs that not only can block the growth, but could also lead to a significant reduction in tumor size.
Keywords: phosphoproteomics; leiomyoma; 2-DE; myometrium; mass spectrometry
1. Introduction
Uterine leiomyomas are benign smooth muscle cell tumors originating from the myometrium.
These tumors can occur in 70–80% of women and are the first gynecological reason why women
undergo hysterectomy [1]. They are responsible for severe health problems, including pain, infertility,
repetitive pregnancy loss and heavy uterine bleeding [2]. To date, little is known about the pathogenesis
of this tumor, and this leads to the lack of a valid medical treatment. Leiomyomas are characterized by
a hyperproduction of extracellular matrix (ECM) [3], and by high interstitial fluid pressure (Pif) [4].
Phosphorylation occurs in target amino acids, usually in serine, threonine, or tyrosine residues [5].
It is known that phosphorylation is the most relevant post-translational protein modification [6] and
that altered phosphorylation in cellular pathways is strongly associated with tumors [7].
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Hermon TL et al. showed that estrogen receptor α (ERα) is significantly more phosphorylated
on serine in the leiomyoma, if compared to the myometrium, and is regulated by ERK1/2 leading
to leiomyoma development [8,9]. Over-phosphorylation of receptor tyrosine kinases (RTKs), that
regulate several cellular processes in tumors, like differentiation and proliferation, is associated with
cell proliferation in the leiomyoma [10]. Signals of other cell membrane receptors, like transforming
growth factor beta (TGF-β), activin, myostatin are transmitted to the nucleus through Smads proteins.
The intracellular effectors of TGF-β signaling lead to the activation of Smad proteins by phosphorylation.
These proteins are transferred to the nucleus, modulating gene expression [11]. In the leiomyoma,
Smad2/3 is over phosphorylated if compared to the myometrium, and the use of GnRH-agonist
treatment induces a reduction in phosphorylation of this protein [12]. Several studies have shown the
dysregulation of the PI3K/Akt/mTOR pathway. Indeed, they find an increase in cyclin D2 and glycogen
synthase kinase 3 (GSK3) and a decrease of phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase
(PTEN) leading to leiomyoma development [13]. There is evidence that the Ras/Raf/MEK/ERK pathway
is dysregulated in the leiomyoma. Several studies have shown that different kinases, such as ERK and
RTK, are altered in this pathway and this may be related to the disease [14,15].
For the reasons described above, the identification of changes in protein phosphorylation levels
in the leiomyoma may be useful for the understanding of the tumor physiopathology. Several
proteomic studies have been conducted and studies have identified proteins involved in leiomyoma
pathology [16,17].
The objective of our study was to create a phosphoproteomic profile by using Pro-Q Diamond
and immobilized metal affinity chromatography (IMAC) of leiomyoma and myometrial tissues, for the
identification of differentially phosphorylated proteins involved in tumorigenic signaling pathways
and in anti-apoptotic and cell survival processes.
2. Materials and Methods
2.1. General
Tissues samples were obtained from seven premenopausal patients who underwent hysterectomy
for symptomatic uterine leiomyomas. All procedures conformed to the Declaration of Helsinki and
were approved by the Review Board of the Institute for Maternal and Child Health–IRCCS “Burlo
Garofolo” (Trieste, Italy). All subjects involved signed a written informed consent. The median age of
patients was 45 years, with a minimum of 36 and a maximum of 48 years.
Oncologic patients; Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis
C virus (HCV) seropositive patients; and patients with adenomyosis were excluded from the study.
The patients had not received hormonal therapy in the three months before surgery.
2.2. Tissue Samples
Two samples were collected from each patient: one from the central area of the leiomyoma and
one from the unaffected myometrium situated more than 2 cm away from the leiomyoma capsule.
All leiomyomas were confirmed histologically as benign ordinary leiomyomas. All leiomyomas were
subserosal/intramural with dimensions ranging from 4 to 6 cm. Samples were stored at −80 ◦C until
proteomic analysis was performed.
2.3. Phosphoprotein Isolation, Pro-Q Diamond and 2-DE
One hundred mg of myometrium and leiomyoma tissue from seven patients were used for
phosphoprotein isolation by Phosphoprotein Enrichment Kit (Pierce). Tissues were homogenized in
(1% NP-40, 50 mM Tris-HCl (pH 8.0), NaCl 150 mM) with Phosphatase Inhibitor Cocktail Set II 1×
(Millipore, Burlington, VT, USA) and 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine.
The concentration of the supernatant was determined by Bradford. Tissue homogenates were then
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diluted to 0.4 mg/ml in lysis buffer provided by the Phosphoprotein Enrichment Kit. Six ml of final
samples were used for isolation of the phosphoprotein according to the manufacturer’s instructions.
2-DE was performed as previously described [18]. For 2-DE analysis, 250 µg of proteins from
each sample (obtained after phosphoproteins enrichment, as specified above) were denatured in
300 µl of dissolution buffer (7 M urea, 2 M thiourea, 4% 3-((3-cholamidopropyl)dimethylammonio)-
1-propanesulfonate, 40 mM Tris, 65 mM dithiothreitol (DTT), and 0.24% Bio-Lyte 3/10 (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) and a trace of bromophenol blue. ReadyStrip™ pH 4–7 18-cm
immobilized pH gradient (IPG) strips (Bio-Rad Laboratories, Inc., Hercules, CA, USA) were rehydrated
in a dissolution buffer at 50 V for 12 h at 20 ◦C, and isoelectric focusing (IEF) was performed in a
PROTEAN IEF Cell (Bio-Rad Laboratories, Inc., Hercules, CA, USA). After the IEF, serial incubations
were performed: first, the IPG strips were equilibrated for 20 min in an equilibration buffer (6 M urea,
2% SDS, 50 mM Tris-HCl (pH 8.8), 30% glycerol and 1% DTT) and then in another equilibration buffer
containing 4% iodoacetamide instead of DTT. For the second dimension, the equilibrated IPG strips
were transferred to a 12% polyacrylamide gel.
After electrophoresis, gels were fixed in 40% methanol and 10% acetic acid for 1 h, and then
stained for 16h with SYPRO Ruby. 2-DE gels were scanned with a Molecular Imager PharosFX System.
Double experimental replicates were performed per sample.
For the experiment with Pro-Q Diamond dye (Thermo Life Technologies, Waltham, MA, USA),
seven patients (the same patients used for phosphoproteome enrichment) were used. One thousand
µg of proteins were used for 2-DE as described above. Gels were first stained with Pro-Q Diamond
dye according to manufacturer’s instructions, washed with water, and scanned with Pharos FX Plus
Molecular Imager (Bio-Rad) to visualize the phosphoproteome. Gels were stained for 16 h with SYPRO
Ruby to reveal the total proteome. Double experimental replicates were performed per each sample.
For all gels, molecular weights were determined by comparison with Precision Plus Protein Pre-stained
Standards (Bio-Rad Laboratories, Inc., Hercules, CA, USA), covering a range from 10 to 250 kDa
and analyzed using the Proteomweaver 4.0 software (both from Bio-Rad Laboratories, Inc., Hercules,
CA, USA).
2.4. Quantification of Spot Levels
2-DE image analysis was performed using the Proteomweaver 4.0 software. The analysis process
was carried out by matching all gels from seven myometria and seven leiomyomas. The Proteomweaver
4.0 algorithm matched all of the gels to find quantitative differences. Differences were considered
significant when the ratio of the mean percentage relative volume (%V) (%V = V(single spot)/V(total
spot)) was ±1.5-fold and satisfied the non-parametric Wilcoxon test (P < 0.05). For Pro-Q Diamond gel
stain, the ratios of relative protein abundance values between the myometrium and the leiomyoma
were calculated. Ratios ≥ 1.5 and ≤ 0.6 were considered as significantly different. The relative protein
abundance of phosphoproteins (P) was calculated in the Pro-Q Diamond images and in the SYPRO
Ruby images, as previously described by Wang and colleagues [19].
2.5. Trypsin Digestion and MS Analysis
Spots from 2-DE were digested and analyzed by mass spectrometry, as described by Ura et al. [20].
After excision from 2-DE gels, the spots were washed four times with 50 mM NH4HCO3 and
acetonitrile (ACN; Sigma-Aldrich, St. Louis, MO, USA) alternatively, and dried under vacuum in a
SpeedVac system. For gel spot digestion, three microliters of 12.5 ng/µL sequencing grade modified
trypsin (Promega, Madison, WI, USA) in 50 mM NH4HCO3 were added, and samples were digested
overnight at 37 ◦C. Peptides extraction was made by three changes of 50% ACN/0.1% formic acid (FA;
Fluka, Ammerbuch, Germany), peptide mixtures were dried under vacuum and stored at −20 ◦C, until
mass spectrometry (MS) analysis was performed.
Samples were dissolved in 10 µL of 5% ACN/0.1% FA and 5 microliters of each sample were
analyzed by LC-MS/MS on a 6520 Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA,
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USA) coupled to a chip-based chromatographic interface. A Large Capacity Chip was used and
peptides were separated in the C18 nano-column (150 mm × 75 µm ID) at a flow rate of 0.3 µL/min.
H2O/FA 0.1% and ACN/FA 0.1% were used as eluents A and B, respectively. Peptides were separated
with a linear gradient of eluent B from 5% to 50% in 15 min and analyzed with a data dependent mode
acquisition: for each MS scan, 6 MS/MS spectra were acquired for the most intense ions. Scan speeds
were 3 MS spectra/sec and 3 MS/MS spectra/sec.
Raw data files were converted into Mascot Generic Format (MGF) files with MassHunter
Qualitative Analysis Software version B.03.01 (Agilent Technologies, Santa Clara, CA, USA) and
searched with Mascot Search Engine (version 2.2.4, Matrix Science, London, UK) through the Proteome
Discoverer Software interface (version 1.4, Thermo Fisher Scientific, Waltham, MA, USA). Spectra
were searched against the human section of the Uniprot database (version July 2018, 95,057 sequences)
using the following parameters: enzyme specificity was set to trypsin with 1 missed cleavage allowed,
precursor and fragment ions tolerance were 20 ppm and 0.05 Da, respectively. Carbamidomethylcysteine
and oxidation of methionine were set as fixed modification and variable modification, respectively.
MS/MS spectra containing less than 5 peaks or with a total ion count lower than 50 were discarded.
The algorithm Percolator was used to assess the False Discovery Rate (FDR) thanks to a concomitant
search against the corresponding randomized database. Proteins were considered as positive hits if
for each protein at least 2 unique peptides were identified with high confidence (FDR < 0.01%). For
some protein spots that did not return any significant hit, a Peptide Mass Fingerprint (PMF) was also
performed with Mascot. All identified proteins were verified to have phosphorylated residues in
PhosphoSitePlus database (www.phosphosite.org).
2.6. Western Blotting
Phosphoprotein extracts (20 µg) from IMAC columns used for 2-DE were separated by 12% and
then transferred to a nitrocellulose membrane. The Western blotting procedure for phosphoproteins
was conducted as previously described [21]. The membrane was blocked by treatment with 5% BSA in
TBS-tween 20. After BSA saturation the membrane was incubated overnight at 4 ◦C with 1:200 diluted
primary rabbit polyclonal antibody against Endoplasmic reticulum chaperone BiP (HSPA5), with 1:300
diluted primary rabbit polyclonal antibody against heat shock protein beta-1 (HSPB1), and 1:800 diluted
primary rabbit polyclonal antibody against Vinculin (VINC). The membrane was washed three times
in TBST for 10 min, and then incubated for 90 min at 4 ◦C with a horseradish peroxidase-conjugated
anti-rabbit immunoglobulin G antibody (Sigma-Aldrich, St. Louis, MO, USA; Merck KGaA, Burlington,
VT, USA) at 1:3.000 dilution. Protein expression was visualized by chemiluminescence (SuperSignal
West Pico Chemiluminescent Substrate; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and the
intensity of the signals was quantified by VersaDoc Imaging System (Bio-Rad Laboratories, Inc.). The
intensities of the immunostained bands were normalized with the protein intensities measured by Red
Ponceau (Sigma-Aldrich, St. Louis, MO, USA; Merck KGaA, Burlington, VT, USA) from the same blot.
2.7. Ingenuity Pathway (IPA) and PANTHER Analysis
Differentially enriched proteins identified by MS in the leiomyoma were analyzed by IPA
(Qiagen GmbH, Hilden, Germany). In IPA, we considered P < 0.05 as a statistically significant value.
Selected genes were used to generate bio-functions. For the filter summary, only associations where
confidence was high (predicted) or that had been experimentally observed were considered. These
proteins were analyzed by PANTHER 11.0 (Protein Analysis Through Evolutionary Relationships;
http://www.pantherdb.org) and Gene Ontology (http://amigo.geneontology.org/rte). Proteins were
then classified according to their involvement in biological processes, molecular function, protein class,
and pathways. Since the majority of the proteins identified participated in multiple processes, only the
most relevant ones were reported.
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2.8. Statistical Analysis
Statistical analyses were carried out with the non-parametric Wilcoxon signed-rank test for
matched samples for both 2-DE and Western blot data. P < 0.05 was considered to indicate a statistically
significant difference. All analyses were conducted with Stata/IC 14.1 for Windows (StataCorp LP,
College Station, TX, USA).
3. Results
3.1. Identification of Differentially Phosphorylated Proteins with Pro-Q Diamond Gel Stain
After electrophoresis, gels were stained with Pro-Q Diamond for phosphoproteins (P) and with
SYPRO Ruby for total proteins (T). Correlation analysis of gel-pairs performed well, with an average
matching efficiency of approximately 80%. As shown in Figure 1, ten protein spots belonging to
seven different putative phosphoproteins were found to be with a significant different abundance
in leiomyoma samples if compared to the myometrium. The spot volume of two of these proteins
[corresponding to Apolipoprotein E (APOE) (spot6) and 60S acidic ribosomal protein P2 (RPLP2)
(spot7)] was significantly higher (>1.5-fold) (Table 1) in the leiomyoma, while for five proteins
(Caveolae-associated protein 1 (CAVN1) (spot1,2,3,4), Heterogeneous nuclear ribonucleoproteins
C1/C2 (HNRNPC) (spot5), Caveolae-associated protein 1 (PTRF) (spot8), Apolipoprotein D (APOD)
(spot9) and Myosin light chain kinase, smooth muscle (MYLK) (spot10)) the relative spot volumes
were significantly lower (<0.6-fold, Figure 1).
Table 1. List of putative phosphoproteins with a significant different abundance in the leiomyoma
compared to myometrium, as identified by mass spectrometry.
Accession
No Spot No Protein Description
Gene
Symbol
Protein
Score
Fold
Change * P-Value
P30101 22 Proteindisulfide-isomerase A3 PDIA3 295 5.2 0.0277
H9KV75 25 Alpha-actinin-1 ACTN1 93 4.9 0.0431
P11021 29
78 kDa
glucose-regulated
protein
HSPA5 675 4.6 0.045
P05387 7 60S acidic ribosomalprotein P2 RPLP2 121 4.5 0.0422
H0YJW3 32 Alpha-actinin-1(Fragment) ACTN1 141 3.8 0.0273
Q5JRR6 34
Ubiquitin-like
modifier-activating
enzyme 1
UBA1 64 3.8 0.0277
A0A087WU08 18 Haptoglobin HP 159 3.4 0.0180
A0A087WU08 19 Haptoglobin HP 50.8 3.3 0.0180
E9PFZ2 30 Ceruloplasmin CP 154 3.2 0.0431
H7BZ94 41 Proteindisulfide-isomerase P4HB 272 3.2 0.0431
A0A0C4DGB6 26 Serum albumin ALB 43 3 0.0220
H7C3T4 15 Peroxiredoxin-4 PRDX4 159 2.85 0.0273
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Table 1. Cont.
Accession
No Spot No Protein Description
Gene
Symbol
Protein
Score
Fold
Change * P-Value
Q5JRR6 33 Ubiquitin-likemodifier-activating enzyme 1 UBA1 128 2.7 0.0273
P02790 27 Hemopexin HPX 69 2.56 0.0431
Q3BDU5 20 Prelamin-A/C LMNA 395 2.5 0.0277
H7BZ94 40 Protein disulfide-isomerase P4HB 72 2.3 0.0277
P18206-2 38 Isoform 1 of Vinculin VINC 198 2.25 0.0277
E9PFZ2 31 Ceruloplasmin CP 237 2.25 0.0431
P30101 25 Protein disulfide-isomerase A3 PDIA3 808 2.23 0.0220
P10809 39 60 kDa heat shock protein HSPD1 234 2.2 0.0431
P02649 6 Apolipoprotein E APOE 230 2.15 0.0431
P01023 37 Alpha-2-macroglobulin A2M 52 2.14 0.0431
P01023 12 Peroxiredoxin-2 PRDX2 64 2.1 0.0180
P04792 14 Heat shock protein beta-1 HSPB1 151 2 0.0277
P01024 17 Complement C3 CO3 171 2 0.0431
E9PN50 21 26S protease regulatory subunit6A (Fragment) PSMC3 191 2 0.0425
P30101 23 Protein disulfide-isomerase A3 PDIA3 79 2 0.0220
B7ZAR1 24 T-complex protein 1 subunitepsilon CCT5 150 2 0.0277
P28070 13 Proteasome subunit beta type-4 PSMB4 168 1.75 0.0431
J3KRH2 11 Haptoglobin (Fragment) HP 342 1.7 0.0178
P08603 36 Complement factor H CFH 69 1.7 0.0273
Q13409-2 28 Isoform 2B of Cytoplasmicdynein 1 intermediate chain 2 DYNC1/2 85 1.51 0.0180
Q6NZI2 4 Caveolae-associated protein 1 CAV1 75 0.65 0.0277
Q6NZI2 2 Caveolae-associated protein 1 CAV1 161 0.43 0.03
Q6NZI2 3 Caveolae-associated protein 1 CAV1 127 0.37 0.0180
G3V5V7 5
Heterogeneous nuclear
ribonucleoproteins C1/C2
(Fragment)
HNRNPC 69 0.29 0.0180
Q6NZI2-3 8 Isoform 3 of Polymerase I andtranscript release factor PTRF 238 0.11 0.0422
C9JF17 9 Apolipoprotein D APOD 103 0.1 0.0422
Q15746-10 10 Isoform 8 of Myosin light chainkinase, smooth muscle MYLK 51 0.08 0.03
P17661 16 Desmin DES 787 0.06 0.0180
Q6NZI2 1 Caveolae-associated protein 1 CAV1 63 0.03 0.0178
* Fold change was defined as the ratio of the mean %V according to the formula %V = Vsingle spot/Vtotal spot of
cases vs. controls.
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Figure 1. (A) Images of gels stained with Pro-Q Diamond to detect phosphoproteins. (B.) Images of
gels stained with SYPRO Ruby for total proteins.
3.2. Enrichment of Immobilized Metal Affinity Chromatography (IMAC)
The next step for the identification of differentially phosphorylated proteins in the leiomyoma was
the using of IMAC. This method, although not completely specific, allows for an efficient enrichment
of phosphoproteins. By using 2-DE fluorescence, we compared the enriched phosphoproteome of the
myometrial and leiomyoma tissues. An average of 1800 spots was detected on gels for both types of
enriched phosphoproteomes. Correlation of gel-pairs performed with an average matching efficiency
of ~80%. The analysis revealed 35 protein spots with a significant different abundance (Figure 2) in
the leiomyoma compared to myometrium. We considered only spots supposedly corresponding to
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phosphoproteins, with fold change in %V ≥1.5 or ≤0.6 in intensity and that were statistically significant
(P < 0.05). Of these spots, 34 were upregulated (>1.5-fold) while one was significantly downregulated
(<0.6-fold) (Table 1). The 33 putative phosphoproteins were identified using a nano-LC-ESI-Q-TOF
system and Mascot search engine, as described above.
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Figure 2. Two-dimensional electrophoresis map of normal myometrium and leiomyoma
phosphoproteome enriched by IMAC columns. Immobilized pH gradient 4–7 strips were used
for the first dimension and 12% polyacrylamide gel was used for the second dimension. The numbered
circles indicate the differentially phosphorylated spots.
3. . Functional Analysis of the L P
The identified proteins were divided into groups, based on the PANTHER classification system
according to their biol gical processes, molecular function, protein class. In terms of biol gical
processes (Figure S1), the proteins were grouped into four main categories: response to stimulus,
cellular process, metabolic process, biol gical regulation. For molecular function (Figure S2), proteins
were grouped into: catalytic activity, binding, molecular function regulator, and transporter activity.
For protein class (Figure S3), proteins wer grouped in five main categories: hydrolase, signaling
molecule, oxidoreductase, enzyme modulator, and defe se/immunity protein. For cellular c mponent
(Figure S4), proteins were grouped in four main categories: cell parts, organelle, protei -containing
complex, extracellular region. For pathway analysis (Figure S5), proteins were g uped in 15 pathways.
Ten of ese (FAS signaling pathway, p38 MAPK pathway, VEGF sign ling pathway, Cytoskelet l
regulation by Rho GTPase, Integrin signali g pathway, Apoptosis signaling pathway, Angiogenesis,
Go adotropin-releasing h rmone receptor pathway, Ubiquitin-proteasome pathway, Inflammation
medi ted by che okin and cytokine signaling pathway) are tumorigenic signaling pathways.
Proteins differentially enriched by IMAC in the leiomyoma compared to the myometrium were
used in the core analysis with IPA software. The top n tworks in which these proteins ar involved
corr spond to 1) Apoptosis (Figure S6A.) and 2) Cell survival (Figure S6B.). In the apoptosis network,
18 putative ph sphopro eins are involved. Of thes , CFH (spot36), DYNC (spot28), HSPA5 (spot29),
HSPB1 (spot14), HSPD1 (spot39), PDRX2 (spo 12), UBA1 (spot33,34), A2M (spot37) are involved
in apopto is inhibition, while HSPA5, HSPB1, HSPD1, LMNA (spot20), P4HB (spot41,42), PRDX2,
PSMB4 ( pot13) are i volved in cell survival. HSPA5, HSPB1, HSPD1 and PDRX2 are involved in both
inhibition of apoptosis and c ll survival.
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3.4. Immunohistochemical Study of Altered Proteins
In this study, we proceeded to verify by immunoblot the alteration of three putative phosphorylated
proteins: HSPA5, HSPB1, and VINC. After IMAC enrichment, the abundance of these proteins in
five leiomyomas was compared to the matched normal myometrial tissue samples (previously used
in 2-DE analysis) by Western blot analysis (Figure 3). The five patients shown in the figure are
representative of the total seven patients included in the study, based on both 2-DE and Western
blotting phosphorylation trend of HSPB1, HSPA5, and VINC (higher in leiomyoma compared to
myometrium). We selected HSPB1 and HSP5A because, based on our bioinformatic analysis, these two
proteins are associate to the inhibition of apoptosis and cell proliferation. We selected VINC because
the antibody is commercially available.
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Figure 3. Western blot analysis was utilized to confirm the alteration of phosphorylation of
proteins HSPB1, VINC and HSPA5 in paired myometrium (M) and leiomyoma (L). The intensity of
immunostained bands was normalized against the total protein intensities measured from the same
blot stained with Red Ponceau. Number 1-5 indicate the patients. The bar graph shows the relative
expression (band density) of HSPB1, VINC and HSPA5 in the myometrium and the leiomyoma. Results
are s own as a histogr m (P < 0.05) and e ch bar represents mean ± standard deviation.
4. Discussion
Several studies have shown that the phosphorylation of certain proteins like ER, AKT, RTK, MAPK,
MEK, and GSK3 lead to increased leiomyoma cell proliferation [8,9,22]. For the first time, we conducted
a proteomic study on leiomyoma and normal myometrium to identify putative phosphoproteins and
the pathways in which these proteins are involved and that are altered in the tumor as compared to
the normal tissue. By using a combination of IMAC enrichment, 2-DE, Diamond Pro-Q staining, and
ass spectrometry, we identified 32 putative phosphoproteins differentially phosphorylated/expressed
in the leiomyoma as compared to the myometrium (Table 1). We identified several tumor-related
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pathways in which these proteins are involved and that could be implicated in the modulation of
leiomyoma growth. According to the data reported in the PhosphoSitePlus database, all identified
proteins were already reported to be phosphorylated in vivo, suggesting that the enrichment procedure
was effective in isolating mainly phosphorylated proteins. The altered abundance or phosphorylation
level of some of these proteins was confirmed by an independent method (IMAC enrichment, 2-DE,
and Western blotting). However, we did not try to identify the phosphorylation site(s) that could be
altered in these proteins and therefore our validation could not be performed using antibodies against
specific phosphorylated sites. Nonetheless, we could confirm a significant difference of these proteins
in tumor vs. normal tissue, either due to an overall altered abundance of the proteins or to an altered
phosphorylation level.
Jamaluddin MFB et al. [14] conducted a proteomic study for the characterization of fibroid ECM
proteins. They identified several proteins up regulated in the leiomyoma: POSTN, TNC, COL3A1,
COL24A1, and ASPN. Another proteomic study conducted by Liu Y et al. [23] identified TRADD as a
potential biomarker in human uterine leiomyoma.
The Fas receptor (CD95) mediates apoptotic signaling initiated by interaction with surface
expressed FasL on other cells [24]. Mutations in the Fas signaling pathway can result in cell
hyperproliferation [25]. Once the complex Fas-FasL has been created, the apoptotic program should be
activated via recruitment of signaling adaptor molecules to the Fas receptor [26].
Lamins constitute a class of intermediate filaments, which, during mitosis, are dissociated
by phosphorylation-dependent mechanisms [27]. To date, no data regarding the activity of the
phosphorylated form of Lamin A have been reported. According to Foster CR and colleagues,
increased mobility of phosphorylated Lamin A could be one way to promote nuclear deformability
and cell migration [28].
The p38 MAPK pathway is regulated by stress, cytokines and mediates a wide variety of cellular
behaviors, such as cell differentiation, proliferation, migration, invasion, and cell death [29].
The VEGF pathway represents the signal transduction cascade, initiated after this protein binds to
its receptor VEGFR-2, leading to survival, increased proliferation, and migration of blood endothelial
cells required for angiogenesis [30]. In the leiomyoma, VEGF is overexpressed and leads to tumor
growth in xenografts mice [31]. In this study, we identified four putative phosphoproteins involved in
anti-apoptotic and cell survival processes, events that promote cell growth.
HSPB1 plays a role in stress resistance and actin organization. In response to environmental
stress, the encoded protein translocates from the cytoplasm to the nucleus and functions as a molecular
chaperone that promotes the correct folding of other proteins and plays an essential role in the
differentiation of a wide variety of cell types [32]. This protein is correlated with poor clinical outcomes
in several human cancers, promoting cancer cell proliferation and metastases, while protecting cancer
cells from apoptosis [33]. In our previous study [34]. We predicted the phosphorylation of HSPB1 in
the leiomyoma. In this study, we identified this protein as supposedly differentially phosphorylated
in the leiomyoma, suggesting a possible role of phosphorylated HSPB1 in promoting cell survival in
cancer [35].
HSPA5 is another putative phosphoprotein identified in this study, involved in cell survival and
anti-apoptotic events. This protein plays a central role in regulating the unfolded protein response
(UPR), is an obligatory component of autophagy in mammalian cells, and plays an important role
in cellular adaptation and oncogenic survival [36,37]. This protein undergoes phosphorylation at
specific serine and tyrosine residues, which influences their oligomerization into larger, multimeric
aggregates [38]. Lim et al. suggest the possibility of a direct role of the phosphorylation of HSP5A in
human breast cancer tissue [39].
HSPD1 is implicated in mitochondrial protein import and macromolecular assembly [40]. This
chaperone promotes the refolding and proper assembly of unfolded polypeptides generated under
stress conditions in the mitochondrial matrix [41]. The tyrosine phosphorylation of HSPD1 is essential
for the maturation of ULBP2 (cell surface proteins that are present in transformed and stressed cells and
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ligands for NK cells) [42]. In cancer, the loss of ULBP2 leads to reduced NK cell-mediated cytotoxicity
and cytokine production [43].
PRDX2 is the last of the identified putative phosphoproteins involved in anti-apoptotic and cell
survival processes. PRDX2 is a member of the peroxiredoxin family of antioxidant enzymes, involved
in redox regulation of the cell [44]. This enzyme influences several cellular processes involving
proliferation, survival, and apoptosis, which suggests a possible role for Prdx2 in the maintenance of
cancer cell [45]. Qu D et al. suggest that the Cdk5 phosphorylate PRDX2 [46]. This phosphorylation
reduces PRDX2 activity thus increasing oxidative stress and cell proliferation [46]. We think that a
similar mechanism may be present in the leiomyoma. Panther analysis revealed a significant enrichment
of GO terms for several important processes, like metabolic processes and cellular biogenesis. Some of
these metabolic processes have been previously described by our group [25]. pointing to a particular
importance of metabolism in leiomyoma growth. In addition, our Panther analysis reveals that many
proteins identified in our study are enzymes, are related to oxidative stress, and reside mostly inside
the cell.
A scrutiny of the literature reveals that three kinases are known to be responsible for the
phosphorylation of several proteins that we have identified in this study. In particular, MAPK, PKC,
and Cdk5 were reported to phosphorylate HSPB1 [47], HSPA5 [48], HSPD1 [49], and PRDX2 [47].
Interestingly, both MAPK and PKC are known to be involved in leiomyoma development [9] and in
general all three kinase are related with cancer cell progression and proliferation [47].
Several studies have been conducted to highlight the effects of various kinase inhibitors in the
leiomyoma. Shushan A et al. [50] used the AG1478 an EGFR kinase blocker in leiomyoma cells.
Leiomyoma cell growth is inhibited by AG1478, and is unaffected by the presence of physiological
concentrations of estradiol and progesterone. In another paper, Shushan A et al. [51] evaluate the
efficiency of genistein (a plant flavonoid) and the new protein tyrosine kinase inhibitor TKS050 in the
inhibition of autophosphorylation of EGFR and downstream signal transduction events, including cell
proliferation and cell cycle progression.
The ubiquitination is a poorly studied process in leiomyoma, even though it is known that
the blocking of this process is related to tumor growth. An example is the switching of the
ubiquitin/proteasome-dependent degradation of RXRα by phosphorylation in leiomyomas. These
events may be responsible for the accumulation of RXRα and the consequent dysregulation of retinoic
acid target genes [52].
UBA1 catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation
through the ubiquitin-proteasome system [53]. The role of this enzyme has been linked to DNA repair,
for response to replication stress, cell cycle regulation, apoptosis, and cancer [54]. UBA1 inhibitors lead
to an unfolded protein response and induces cell death in malignant cells over normal cells [55].
5. Conclusions
In conclusion, our study highlights the involvement of the phosphoproteome in leiomyoma
growth. We identified several pathways associated with tumor development and phosphoproteins
involved in the inhibition of apoptosis and cell proliferation. All these data show the existence of
a relation between phosphorylation and leiomyoma development. Further studies are needed to
understand the role of phosphorylation in leiomyoma growth. In our opinion, our data represent a
step forward in the difficult understanding of the molecular mechanisms that lead to the formation
and development of the leiomyoma.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/5/691/s1,
Figure S1: PANTHER classification of identified proteins in the leiomyoma according to their biological process,
Figure S2: PANTHER classification of identified proteins in the leiomyoma according to their molecular function,
Figure S3: PANTHER classification of identified proteins in the leiomyoma according to their protein class,
Figure S4: PANTHER classification of identified proteins in the leiomyoma according to their cellular component,
Figure S5: PANTHER classification of identified proteins in signaling pathways, Figure S6: Network build up
from one of the most significant bio-functions: 1. Apoptosis, 2. Cell survivor.
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